A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
A phase 3 trial of Nivolumab in hepatocellular carcinoma, run by Bristol-Myers Squibb, active and no longer recruiting.
Overview
A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation is a phase 3 interventional study registered as NCT03383458 by Bristol-Myers Squibb, with 545 participants enrolled, started 2018-04-18 and due to reach its primary completion in 2026-05-27. Interventions recorded: Nivolumab, Placebo. Conditions listed: Hepatocellular Carcinoma, Liver Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialCombination of TATE and PD-1 Inhibitor in Liver Cancer
Shares Nivolumab, Hepatocellular carcinoma.
- TrialA Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors
Shares Bristol Myers Squibb, Nivolumab.
- TrialEffectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma
Shares Bristol Myers Squibb, Nivolumab.
- TrialA Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advance
Shares Bristol Myers Squibb, Nivolumab.
- TrialCVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma
Shares Nivolumab, Hepatocellular carcinoma.
- TrialA Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
Shares Bristol Myers Squibb, Nivolumab.
- TrialA Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer
Shares Bristol Myers Squibb, Nivolumab.
- TrialA Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma
Shares Bristol Myers Squibb, Nivolumab.